
ASSESSING THE QUALITY AND PRECISION OF THERAPEUTIC ANTIBODY LC/MS DATA ACQUIRED AND PROCESSED USING AUTOMATED WORKFLOWS

<u>Scott J. Berger</u> and Asish. B. Chakraborty Biopharmaceutical Sciences, Waters Corporation, Milford, MA

OVERVIEW

- ♦ A significant amount of antibody characterization can be accomplished by intact LC/MS analysis of the antibody and its reduced subunits.
- ◊ Protein-level analyses provide a "holistic view" of the molecule, including verification of primary structure, and profiling of common glycosylation and processing variants.
- ♦ While such analyses are straightforward, many labs struggle to generate robust and reproducible methodologies for routine antibody characterization.
- ♦ Our group has identified an optimized chromatographic configuration, and focused on developing robust automated methods for generating high-quality antibody LC/MS data.
- ♦ In this poster, we illustrate two rapid, efficient, and reproducible methodologies for Open Access (Walkup sample submission) LC/MS profiling of the intact and reduced structures of an $IgG1_k$ monoclonal antibody.


SYSTEM CONFIGURATION




UPLC/LCT Premier XE Desalting LC/MS Configuration

- LC/MS data were acquired using an ACQUITY UPLC[™] system coupled with an LCT Premier[™] orthogonal time-of-flight MS (Waters) operating in ESI+ V-mode.
- Desalting and reversed phase separations were accomplished on a 2.1 x 5 mm MassPREPTM Micro Desalting column (Waters).
- A system controlled post-column 2-position valve was used for diversion of buffers and salts present in the sample.
- MassLynx 4.1 and the included OpenLynx application manager were used for Open Access data acquisition, and automated processing of the LC/MS data (Peak detection, spectral summation, deconvolution and component quantitation).

Time (min)	%В	Flow (ml/min)	Curve
0.00	5	0.5	Initial
0.50	5	0.5	6
0.51	5	0.2	6
2.0	90	0.2	6
2.1	5	0.5	6
2.7	90	0.5	6
2.8	5	0.5	6
3.4	90	0.5	6
3.5	5	0.5	6
4.0	5	0.5	6





Combined ESI-TOF mass spectra of an intact IqG1 demonstrating regeneration to pre-injection conditions w/o the need of an inter-sample blank run.

TO DOWNLOAD A COPY OF THIS POSTER, VISIT WWW.WATERS.COM/POSTERS


Injection Number

An average relative intensity CV of ~5% was achieved for all major IgG1 glycovariants over the 48 injection series.


Time	%В	Flow
(min)		(ml/mir
0.00	5	0.2
0.50	5	0.2
0.51	10	0.2
7.61	50	0.2
8.0	90	0.5
8.1	5	0.5
8.6	90	0.5
8.7	5	0.5
9.2	90	0.5
9.3	5	0.5
9.8	5	0.5

Combined mass spectra (insets) and deconvoluted mass spectra of the light (LEFT) and heavy (RIGHT) chain subunits of an IgG1.





25 reduced IqG1 samples were analyzed using an OpenLynx automated acquisition and data processing method. The average mass measurement precision for the light chain (not shown) and three major heavy chain glycovariants were ~ 3 ppm.



An average intensity CV of 1.6% for all heavy chain glycovariants (0.5% for light chain) was achieved over the 25 injection sample series.

CONCLUSIONS

- A generic LC/MS configuration and methodology for Open Access intact (and reduced) antibody analysis has generated robust qualitatative and quantitative results with run cycle times of only four (or ten) minutes, no intersample blank injections, and automated data processing.
- This improved throughput and performance of this automated methodology should permit laboratories to better handle the increasing pipelines and assay demands now common to the biopharmaceutical industry.